Results 61 to 70 of about 25,818 (186)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence

Cancer Medicine, 2022
Background Anaplastic lymphoma kinase (ALK) fusion is a prognostic indicator for patients with non‐small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real‐world data of ALK TKIs remain a major concern.
Yurong Wang, Shujing Shen, Peizhu Hu, Di Geng, Ruipan Zheng, Xingya Li   +5 more
doaj   +1 more source

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors [PDF]

, 2016
Background ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors.
Anthony Tolcher, Erkut Bahceci, Geoffrey Yuen, Howard A. Ball, Jung Wook Park, Michael L. Maitland, Patricia LoRusso, Sai-Hong Ignatius Ou, Tianhong Li   +8 more
core   +3 more sources

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer

Case Reports in Oncology, 2013
We report the case of a 50-year-old male former smoker. He was diagnosed as having lung adenocarcinoma and treated with induction chemoradiation therapy followed by surgery and adjuvant chemotherapy.
Yuka Kuriyama, Young Hak Kim, Hiroki Nagai, Hiroaki Ozasa, Yuichi Sakamori, Michiaki Mishima   +5 more
doaj   +1 more source

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 802-811, March 2026.
A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo‐worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine‐based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function.
Michael I. Sponfeldner, Pauline Dürr, Phyllis Lensker, Katja Gessner, Lisa Cuba, Rainer Fietkau, Markus F. Neurath, Bernd Wullich, Marianne Pavel, Carola Berking, Matthias W. Beckmann, Andreas Mackensen, Frank Dörje, Martin F. Fromm   +13 more
wiley   +1 more source

Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective [PDF]

, 2015
Nephrotoxicity is a common adverse effect of many chemotherapeutic agents. The agents most commonly associated with chemotherapy-associated nephrotoxicity are methotrexate, semustine, streptozocin, mithramycin, and cisplatin.
Goodwin, Scott C., Gulati, Rajesh, Jia, Jemianne Bautista, Lall, Chandana, Lamba, Ramit, Tirkes, Temel   +5 more
core   +1 more source

Crossing the Blood–Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy

Advanced Science, Volume 13, Issue 7, 3 February 2026.
Molecularly imprinted polymeric nanocarriers (nanoMIPs) offer robust, antibody‐mimetic platforms to overcome the blood‐brain barrier. The article surveys nanoMIP design and ligand‐directed surface engineering that harness receptor‐mediated transcytosis, and highlights therapeutic and diagnostic applications in neurodegeneration, brain tumors and ...
Ranjit De, Shuliang Shi, Kyong‐Tai Kim
wiley   +1 more source

A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. [PDF]

, 2012
Metastatic non-small cell lung cancer (NSCLC) carries a dismal prognosis. Clinical evidence suggests the existence of an intermediate, or oligometastatic, state when metastases are limited in number and/or location.
Niibe, Yuzuru, Patel, Pretesh R, Salama, Joseph K, Urbanic, James J, Yoo, David S   +4 more
core   +3 more sources

A Giant Thoracic ALK‐Rearranged Mesenchymal Neoplasm in a Child

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background Mesenchymal neoplasms characterized by ALK fusions mainly include inflammatory myofibroblastic tumors (IMTs) and epithelioid fibrous histiocytomas (EFHs). More recently, ALK‐rearranged mesenchymal tumors that are not IMTs or EFHs, characterized by S100 and CD34 coexpression, have been reported in a few small series and isolated case
Sheng Gao, Junhua Wu, Jun Fan, Xiaona Chang, Bo Huang, Danju Luo, Jun He, Heshui Shi, Xiaochuan Dong, Xiu Nie   +9 more
wiley   +1 more source